BETHESDA, Md., March 24, 2015 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a
biotechnology company developing DCVax® personalized immune
therapies for cancer, announced today that Dr. Marnix Bosch, Chief Technical Officer, will
present at the 2nd Immunotherapy of Cancer Conference,
ITOC-2, being held in Munich,
Germany from March 25-27,
2015.
The Company's presentation will take place on Thursday, March 26 at 2:40
p.m. local time (9:40 a.m.
EDT) in Auditorium A at Hörsaal A, Klinikum rechts
der Isar, TU Munich, Ismaniger Str.
22. There will be a live audio webcast of the 15 minute
presentation available at http://nwbio.com/webcasts/.
During his presentation, Dr. Bosch will discuss data relating to
51 patients with Glioblastoma multiforme (GBM) brain cancer who
were treated with DCVax-L on a compassionate basis in an
"Information Arm" outside of the Company's Phase III clinical
trial. These patients were not eligible for the clinical
trial because they were already showing some actual or apparent
re-growth of their brain tumor in imaging at a Baseline Visit when
they finished 6 weeks of daily radiotherapy and chemotherapy
following the surgical removal of their original tumor as part of
the standard of care. Such patients are considered either
"rapid progressors" or "pseudo-progressors," based upon whether the
appearance of early tumor re-growth can be subsequently confirmed.
Dr. Bosch will discuss survival data relating to such
patients.
The ITOC conference will focus on topics such as
immunomodulatory agents, anti-cancer vaccines, adoptive and
engineered T cell Therapy and monoclonal antibodies. The Society
for Immunotherapy of Cancer is partnering with The Cancer Drug
Development Forum for this conference.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both
the United States and
Europe. The Company has a broad platform technology for DCVax
dendritic cell-based vaccines. The Company's lead program is
a 348-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal form
of brain cancer, and is an "orphan disease." The Company is
under way with a 60-patient Phase I/II trial with DCVax-Direct for
all inoperable solid tumors cancers, with a primary efficacy
endpoint of tumor regression. It has completed enrollment in
the Phase I portion of the trial. The Company previously
received clearance from the FDA for a 612-patient Phase III trial
in prostate cancer. The Company conducted a Phase I/II trial
with DCVax for metastatic ovarian cancer together with the
University of Pennsylvania. In
Germany, the Company has received approval of a 5-year Hospital
Exemption for the treatment of all gliomas (brain cancer) patients
outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's ongoing
ability to raise additional capital, risks related to the Company's
ability to enroll patients in its clinical trials and complete the
trials on a timely basis, uncertainties about the clinical trials
process, uncertainties about the timely performance of third
parties, risks related to whether the Company's products will
demonstrate safety and efficacy, risks related to the Company's and
Cognate's abilities to carry out the intended manufacturing
expansions contemplated in the Cognate Agreements, risks related to
the Company's ability to carry out the Hospital Exemption program
and risks related to possible reimbursement and pricing.
Additional information on these and other factors, including Risk
Factors, which could affect the Company's results, is included in
its Securities and Exchange Commission ("SEC") filings.
Finally, there may be other factors not mentioned above or included
in the Company's SEC filings that may cause actual results to
differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation
to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.
Logo -
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nw-bio-to-present-at-the-2nd-immunotherapy-of-cancer-conference-itoc-2-300055111.html
SOURCE Northwest Biotherapeutics, Inc.